Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for Journey Medical (DERM) over the last 6 years, with Q3 2025 value amounting to -$1.4 million.

  • Journey Medical's Change in Accured Expenses fell 388333.33% to -$1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year increase of 2894444.44%. This contributed to the annual value of -$2.9 million for FY2024, which is 40405.41% down from last year.
  • Latest data reveals that Journey Medical reported Change in Accured Expenses of -$1.4 million as of Q3 2025, which was down 388333.33% from -$449000.0 recorded in Q2 2025.
  • Journey Medical's 5-year Change in Accured Expenses high stood at $14.3 million for Q2 2021, and its period low was -$10.5 million during Q3 2021.
  • In the last 5 years, Journey Medical's Change in Accured Expenses had a median value of -$395000.0 in 2021 and averaged -$27421.1.
  • The largest annual percentage gain for Journey Medical's Change in Accured Expenses in the last 5 years was 186214.51% (2025), contrasted with its biggest fall of 388333.33% (2025).
  • Over the past 5 years, Journey Medical's Change in Accured Expenses (Quarter) stood at -$2.1 million in 2021, then soared by 175.89% to $1.6 million in 2022, then surged by 169.41% to $4.3 million in 2023, then tumbled by 67.23% to $1.4 million in 2024, then tumbled by 196.12% to -$1.4 million in 2025.
  • Its last three reported values are -$1.4 million in Q3 2025, -$449000.0 for Q2 2025, and $5.6 million during Q1 2025.